China Financial Statements From 2010 to 2024

CPHI Stock  USD 0.32  0.01  1.56%   
China Pharma financial statements provide useful quarterly and yearly information to potential China Pharma Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on China Pharma financial statements helps investors assess China Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting China Pharma's valuation are summarized below:
Gross Profit
349.3 K
Profit Margin
(0.44)
Market Capitalization
4.7 M
Enterprise Value Revenue
1.1869
Revenue
M
We have found one hundred twenty available fundamental signals for China Pharma Holdings, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of China Pharma Holdings prevailing fundamentals against the fundamentals between 2010 and 2024 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 1.9 M. Enterprise Value is estimated to decrease to about 5 M

China Pharma Total Revenue

6.66 Million

Check China Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among China main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.9 M, Interest Expense of 349.9 K or Selling General Administrative of 1.4 M, as well as many exotic indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0019 or PTB Ratio of 0.26. China financial statements analysis is a perfect complement when working with China Pharma Valuation or Volatility modules.
  
This module can also supplement various China Pharma Technical models . Check out the analysis of China Pharma Correlation against competitors.

China Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets15.6 M16.5 M67.1 M
Slightly volatile
Short and Long Term Debt Total7.4 M4.6 MM
Very volatile
Other Current Liabilities2.7 M2.6 M3.5 M
Very volatile
Total Current Liabilities9.4 M6.8 M10.6 M
Very volatile
Property Plant And Equipment Net13.2 M7.2 M16.6 M
Very volatile
Accounts Payable1.7 M966.4 K1.7 M
Slightly volatile
Cash2.8 M1.4 MM
Pretty Stable
Non Current Assets Total9.9 M10.5 M36.3 M
Slightly volatile
Cash And Short Term Investments2.8 M1.5 MM
Pretty Stable
Net Receivables629.3 K662.4 K15 M
Slightly volatile
Common Stock Total Equity37.5 K52.4 K41.7 K
Slightly volatile
Common Stock Shares OutstandingM3.4 MM
Slightly volatile
Liabilities And Stockholders Equity15.6 M16.5 M67.1 M
Slightly volatile
Non Current Liabilities Total3.5 M2.2 M5.1 M
Pretty Stable
Other Stockholder Equity20.6 M35.3 M23.3 M
Slightly volatile
Total Liabilities13 MM15.6 M
Pretty Stable
Property Plant And Equipment Gross39.1 M37.2 M24 M
Slightly volatile
Total Current Assets5.7 MM30.9 M
Slightly volatile
Short Term Debt4.4 M3.2 M4.5 M
Slightly volatile
Common Stock10.1 K10.6 K39.2 K
Very volatile
Current Deferred Revenue86 K90.5 K847.5 K
Slightly volatile
Inventory3.5 M3.7 M10.8 M
Slightly volatile
Other Current Assets104.7 K110.3 KM
Slightly volatile
Intangible Assets3.4 M3.7 M1.7 M
Pretty Stable
Other Liabilities718.4 K948.1 K688.4 K
Slightly volatile
Other Assets54.3 K57.1 K18.6 M
Slightly volatile
Property Plant Equipment17.9 M15.4 M18.1 M
Very volatile
Net Tangible AssetsM5.3 M59.6 M
Slightly volatile
Capital Surpluse26 M28.1 M24.2 M
Slightly volatile
Long Term Debt Total3.5 M1.9 M5.3 M
Slightly volatile
Short and Long Term Debt4.3 M3.1 M7.9 M
Slightly volatile
Net Invested Capital18.7 M12 M36.9 M
Slightly volatile
Capital Stock10.1 K10.6 K41.6 K
Pretty Stable

China Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense349.9 K333.6 K438.8 K
Very volatile
Selling General Administrative1.4 M1.5 MM
Slightly volatile
Total Revenue6.7 MM20.4 M
Slightly volatile
Other Operating Expenses12.3 M9.8 M13.8 M
Slightly volatile
Cost Of Revenue14.4 M7.5 M16.8 M
Slightly volatile
Selling And Marketing Expenses741.3 K780.3 K138.5 M
Slightly volatile
Non Operating Income Net Other4.9 K5.1 K148.9 K
Pretty Stable
Interest Income4.8 K5.1 K437.5 K
Slightly volatile
Reconciled Depreciation2.4 M2.7 M3.1 M
Slightly volatile

China Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.8 MM3.2 M
Pretty Stable
Depreciation1.9 M2.8 M2.4 M
Slightly volatile
End Period Cash Flow2.8 M1.4 MM
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.280.29215.5144
Slightly volatile
Dividend Yield0.00190.00210.0023
Slightly volatile
Days Sales Outstanding32.7634.4834146
Slightly volatile
Average Payables1.4 M717.2 K1.6 M
Slightly volatile
Stock Based Compensation To Revenue0.01060.01110.2935
Slightly volatile
EV To Sales0.710.749816.838
Slightly volatile
Inventory Turnover1.482.01261.8412
Slightly volatile
Days Of Inventory On Hand248181228
Slightly volatile
Payables Turnover14.377.77739.6115
Very volatile
Sales General And Administrative To Revenue0.20.20910.399
Slightly volatile
Average Inventory3.2 M3.3 MM
Slightly volatile
Research And Ddevelopement To Revenue0.03880.03420.0319
Very volatile
Cash Per Share0.80.44031.2184
Slightly volatile
Payout Ratio0.050.05630.0613
Slightly volatile
Days Payables Outstanding69.0546.931276.4883
Slightly volatile
Intangibles To Total Assets0.230.22180.0522
Slightly volatile
Current Ratio0.840.87922.4318
Slightly volatile
Receivables Turnover9.7410.58488.2965
Slightly volatile
Graham Number6.386.716241.0461
Slightly volatile
Average Receivables555.7 K584.9 K12.4 M
Slightly volatile
Revenue Per Share1.972.07227.0952
Pretty Stable
Interest Debt Per Share1.381.45645.2341
Very volatile
Debt To Assets0.360.2790.2912
Very volatile
Operating Cycle205216384
Slightly volatile
Days Of Payables Outstanding69.0546.931276.4883
Slightly volatile
Dividend Payout Ratio0.050.05630.0613
Slightly volatile
Ebt Per Ebit1.291.11881.8585
Pretty Stable
Quick Ratio0.30.31551.3796
Slightly volatile
Net Income Per E B T3.112.961.3734
Slightly volatile
Cash Ratio0.220.20880.2512
Pretty Stable
Days Of Inventory Outstanding248181228
Slightly volatile
Days Of Sales Outstanding32.7634.4834146
Slightly volatile
Fixed Asset Turnover0.920.97151.8967
Slightly volatile
Debt Ratio0.360.2790.2912
Very volatile
Price Sales Ratio0.280.29215.5144
Slightly volatile
Asset Turnover0.40.42570.3286
Slightly volatile

China Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.9 MM37.7 M
Slightly volatile
Enterprise ValueM5.3 M43.6 M
Slightly volatile

China Fundamental Market Drivers

Cash And Short Term Investments1.5 M

China Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About China Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include China Pharma income statement, its balance sheet, and the statement of cash flows. China Pharma investors use historical funamental indicators, such as China Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although China Pharma investors may use each financial statement separately, they are all related. The changes in China Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on China Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on China Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in China Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue90.5 K86 K
Total RevenueM6.7 M
Cost Of Revenue7.5 M14.4 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.21  0.20 
Research And Ddevelopement To Revenue 0.03  0.04 
Capex To Revenue(0)(0)
Revenue Per Share 2.07  1.97 
Ebit Per Revenue(0.39)(0.41)

Pair Trading with China Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if China Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in China Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against China Stock

  0.81VKTX Viking Therapeutics Potential GrowthPairCorr
  0.79ELEV Elevation Oncology Earnings Call This WeekPairCorr
  0.73NRSNW NeuroSense TherapeuticsPairCorr
  0.59XFOR X4 Pharmaceuticals Earnings Call This WeekPairCorr
  0.54LLY Eli Lilly Earnings Call This WeekPairCorr
The ability to find closely correlated positions to China Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace China Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back China Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling China Pharma Holdings to buy it.
The correlation of China Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as China Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if China Pharma Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for China Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:
Check out the analysis of China Pharma Correlation against competitors.
Note that the China Pharma Holdings information on this page should be used as a complementary analysis to other China Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for China Stock analysis

When running China Pharma's price analysis, check to measure China Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China Pharma is operating at the current time. Most of China Pharma's value examination focuses on studying past and present price action to predict the probability of China Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China Pharma's price. Additionally, you may evaluate how the addition of China Pharma to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Is China Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.91)
Revenue Per Share
2.072
Quarterly Revenue Growth
(0.26)
Return On Assets
(0.10)
Return On Equity
(0.52)
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.